Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma

Data originating from patient samples

The Amsterdam UMC, tumor genome analysis core, allows access to published datasets upon written application and signature of a Data Access Agreement (DAA). In addition, applications to clinical datasets require approval by a Data Access Committee (DAC), who assess whether the proposed work is allowed given patient consent, as well as the scientific purpose. To aid this process we ask you to provide the information below. Requests will be prioritised according to novelty of the research question. Applications with insufficient detail on objectives, justification, and methods/planned analyses are unlikely to be accepted. 1.Reference number for the dataset 2.Full legal name and address of university/institution 3.Name(s) of the Principle Investigator who will use the data: 4.Name(s) and job title(s) of any other investigators who will use the data: 5.Please provide a minimum of one reference to a publication that can be found on PubMed and where the Principle Investigator is an author: 6.How will the data be stored and where will it be stored? 7.What is the proposed study title and what are the objectives and outcomes of the study in which the data will be used 8.Please provide a brief justification or rationale for the proposed study (max 250 words) 9.Please provide a brief description of planned data analyses (max 250 words): 10.Will the results arising from use of the data be used for the creation of products for sale or for any commercial purpose?